A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia

References

• Morgan D A., Ruscetti F. W., Gallo R. W. Selective in vitro growth of lymphocytes from normal human bone marrow. Science 1976; 193: 1007–1011
   PubMed Web of Science ®Google Scholar
• Rosenberg A., Lotze M. T., Muul L. M., Chang A., Avis R., Leitman S., Linehan M., Robertson L., Lee R., Rubin J., Seipp C., Simpson C., White D. A progress report on the treatment of 157 patients with advanced cancer using activated killer cells and interleukine-2 or high dose interleukine-2 alone. N Engl J Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens R., Brandely M., Olive D., Lopez M., Sainty D., Marit G., Stoppa A. M., Reiffers J., Gratecos N., Bertau-Perez P., Mannoni P., Mawas C., Hercend T., Sebahoun G., Carcassonne Y. High-dose recombinant interleukine-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182–2187
   PubMed Web of Science ®Google Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Gavosto F., Mandelli F. Treatment of acute myeloid leukemia patients with recombinant Interleukin-2: a pilot study. Br J Hematol 1991; 77: 491–496
   PubMed Web of Science ®Google Scholar
• Lim S. H., Newland A. C., Kelsey S., Bell A., Offerman E., Rist C., Gozzard D., Bareford D., Smith M. P., Goldstone A. H. Continuous intravenous infusion of high-dose recombinant Interleukin-2 for acute myeloid leukemia - a phase II study. Cancer Immunol Immunother 1992; 34: 337–342
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C., Storb R. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N EnglJ Med 1979; 300: 1068–1070
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringden O., Ozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Lefever A. V., Shih C. Y. Analysis of effector cells in the graft versus leukemia reaction and their relation to graft versus host disease. T-cell depletion in allogeneic bone marrow transplantation. Proceedings Of The Serono Symposia. Ares-Serono Symposia, RomeItaly. M F Martelli, F Grignani, Y Reisner. 1988; 73
   Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Murray C., Bohuon C., Ythier A., Ritz J. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J. L., Leblond V., Michallet M., Dreyfus F., Ifrah N., Bordigoni A. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemia. Lancet 1987; 25: 175–176
   Google Scholar
• Kolb H. J., Schattenberg Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D. Graft versus leukemia effect of donor lymphocyte transfusion in marrow grafted patients. European Group of Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 56: 2041–2045
   Google Scholar
• Foa R., Fierro M. T., Cesano A., Guarini A., Bonferroni M., Raspadori D., Miniero R., Lauria F., Gavosto F. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 1991; 78: 1041–1046
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Bailly M., DorÉ J. F. Inducibility of lymphokine-activated killer cells in patients with acute myelogenous leukemia in complete remission and its clinical relevance. Br J Haematol 1991; 77: 328–334
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Tosti S., Meloni G., Gavosto F., Mandelli F. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant Interleukin-2. Leukemia and Lymphoma 1990; 1: 113–117
   PubMedGoogle Scholar
• Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti S., Tos A. G., Mandelli F. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood M 1994; 2158–2163
   Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flanrin G., Galton D. A.G., Gralrrick H. R., Sultan C. Proposal for the classification of the acute leukemia. Br J Hematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Cassileth P. A., Head D. R, Schiffer C. A., Bennett J. M., Bloomfield C D., Brunning R., Gale R. P., Greever M. R., Keating M. J., Sawitsky A., Stass S., Weinstein H., Woods W. G. Report of the National Cancer Institute-sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Preisler H. D. Treatment failure in AML. Blood Cells 1982; 8: 585–602
   PubMedGoogle Scholar
• Hawkins M. J. Interleukin-2 antitumor and effector cell responses. Sem Oncol 1993; 6(suppl 9)52–59
   Google Scholar
• Olive D., Chambost H., Sainty D., Stoppa A. M., Blaise D., El Marsafy S., Brandely M., Mannoni P., Mawas C., Maraninchi D. Modifications of leukemic blast cells induced by in vivo high-dose recombinant Intetleu-kin-2. Leukemia 1994; 8: 1230–1235
   PubMed Web of Science ®Google Scholar
• Attal M., Blaise D., Marit G., Payen C., Michallet M., Vernant J. P., Sauvage C., Troussard X., Nedellec G., Pico J., Guguet E., Stoppa A. M., Broustet A., Sotto J. J., Pris J., Maraninchi D., Reiffers J. Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995; 86: 1619–1628
   PubMed Web of Science ®Google Scholar
• Baumgarten E., Schmid H., Pohl U., Brzoska J., Linder-Kamp C., Siegert W., Henze G. Low-dose natural interleukin-2 and recombinant Interferon-Gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Leukemia 1994; 8: 850–855
   PubMed Web of Science ®Google Scholar
• Blaise D., Attal M., Pico J. L., Reiffers J., Stoppa A. M., Bellanger C., Molina L., Nedellec G., Vernant J. P., Legros M., Gabus R., Huguet F., Brandely M., Hercend T., Olive D., Maraninchi D. The use of a sequential high-dose recombinant Interleukin-2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leak and Lymph 1997; 25: 469–478
   PubMed Web of Science ®Google Scholar
• Foa R. Does Interleukin-2 have a role in the management of acute leukemia?. J. Clin. Oncol. 1993; 11: 1817–1825
   PubMed Web of Science ®Google Scholar
• Singer C. R.J., Tansey P J., Burnett A. K. T lymphocyte reconstitution following autologous bone marrow transplantation. Clin Exp Immunol 1983; 51: 455–460
   PubMed Web of Science ®Google Scholar
• Charmot D., Ragueneau M., Olive D., Maraninchi D., Mawas C. Generation of CD8 cytolytic T-cells early after autologous or allogeneic bone marrow transplantation. Bone Marrow Transplantation 1987; 2: 183–194
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Drexler H. G., Hazlehurst G., Hoffbrand A. V., Prentice H. G., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Higuchi C M., Thompson J. A., Cox T., Lindgren C. G., Buckner C D., Fefer A. Lymphokin-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989; 49: 5509–5513
   PubMed Web of Science ®Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Murray C., Bohuon C., Ythier A., Ritz J. Characterization of Natural Killer cells with Antileukemia Activity Following Allogeneic Bone Marrow Transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Stoppa A. M., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., Mannoni P., Palmer P., Francks C., Philip T., Maraninchi D. Hematologic and immunologic effects of the systemic administration of recombinant Interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Benyunes M. C., Massumoto C., York A., Higushi C M., Buckner C D., Thompson J. A., Petersen F. B., Fefer A. Interleukin-2 with or without lymphokin-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 1993; 12: 159–163
   PubMed Web of Science ®Google Scholar
• Hamon D., Prentice H. G., Gottlieb D. J., Macdonald I. D., Cunningham J. M., Smith O. P., Gilmore M., Gandhi L., Collis C. Preliminary report. Immunotherapy with interleukin-2 after ABMT in acute myelogenous leukemia. Bone Marrow Transplant 1993; 11: 399–401
   PubMed Web of Science ®Google Scholar